The director at AbbVie highlighted where atogepant stands among the increasing treatment landscape of anti-calcitonin gene-related peptide options within the migraine treatment landscape.
"The safety and tolerability profile in the package we submitted for FDA approval was robust and impressive. Dr. [Jessica] Ailani talked about the adverse events. We saw very few safety issues. We saw constipation about 7% [of the time] and a slightly lower rate of nausea, both of which were overwhelmingly mild.”
In March, AbbVie announced that its orally administered calcitonin gene-related peptide atogepant had its new drug application accepted by the FDA for the preventive treatment of migraine in adults with episodic migraine. With a regulatory decision expected to come in the third quarter of 2021, the drug aims to join a landscape that features the recent approval of fremanezumab (Ajovy; Teva Pharmaceuticals) which earned green light in September 2018.
At the 2021 American Academy of Neurology (AAN) Annual Meeting, April 17-22, atogepant continued to prove its efficacy and safety in a number of abstracts stemming from the phase 3 ADVANCE study. Lawrence Severt, MD, PhD, was among the authors of the study and claims that there are a multitude of advantages atogepant brings to the table, including the oral administration, which is a priority for some patients.
Severt, director, AbbVie, sat down with NeurologyLive about the growth of the CGRP treatment market and the mechanistic benefits they bring as well as harps on the advantages atogepant could bring to the landscape pending continued regulatory success.
For more coverage of AAN 2021, click here.